Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
2d agoen
From the article
Conditions : Systemic Lupus Erythematosus Interventions : Combination Product: Anifrolumab: SC formulation via AI; Combination Product: Anifrolumab: IV formulation; Combination Product: Anifrolumab: SC formulation via aPFS Sponsors : AstraZeneca; Parexel Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus
This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce
lupus.bmj.com·27d agoAnixa Biosciences Aktie: Höchste Lira-cel-Dosis erreicht
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.